Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.

The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field.

NEWPORT BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company"), today announced the execution of a First Amendment to its Development and License Agreement (the "Amendment") with strategic partner Yuva Biosciences, Inc. ("Yuva Biosciences"). The Amendment formalizes the launch of a three-phase Expansion Program to advance all four AI-discovered compounds toward lead compound nomination and updates key terms of the underlying agreement, including AI Development Program scope, the IP framework, governing developed technology, the field of use definitions, and associated financial terms.

The Expansion Program is a structured, three-phase development plan that builds directly on the positive Phase III results announced on July 1, 2026, in which four small-molecule candidates selected by Yuva Biosciences’ proprietary MitoNova™ AI-powered platform demonstrated statistically significant increases in ANT1, a mitochondrial protein central to skeletal muscle energy metabolism, in primary human skeletal muscle cells. Each Expansion Program phase is designed to progressively de-risk the validated compounds while narrowing the compound set toward a nominated lead.